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ABSTRACT 
Incorrect inhaled drug delivery technique is a common problem in paediatric asthma 
[1-4]. Previously, device technique training has been shown to significantly improve 
inhaler skills, using subjective methods, namely check-list analysis [5-8]. However, 
more objective measures are needed to examine more comprehensively the effect of 
training in preschool children and parents. 
Resistance to regular asthma therapy is also a frequent problem when attempting to 
treat young children. Reasoning with young children can be very difficult and parents 
often have to struggle with their child to achieve compliance [2]. The Funhaler spacer 
(FH) (Funhaler™; InfaMed, Australia) has been developed in an attempt to resolve 
this issue by incorporating incentive toys to distract the child from the drug delivery 
process. Based on parental questiom1aire, the FH has been shown to improve 
inhalation technique and increase medication compliance in young children over a 
two-week period [1]. 
A total of 4 7 children participated in the present study; 24 were randomised to a 
standard Aerochamber plus spacer (AC+) (15 male, mean age 63.7 months, range 30-
90 months), and 23 were randomised to the FH spacer (14 male, mean age 60.5 
months, range 36-90 months). Of the 47, four children (AC+: n=2, FH: n=2), with a 
mean age of 51 months (36-60 months) were identified as nose breathers, and were 
analysed as a separate group. The results from the present study show that repeated 
clinic-based technique training had no significant effect on drug delivery (p=O.l51 ). 
Furthermore, it was fo~rid that in the clinic setting, children who were using the FH 
11 
spacer were more likely to 'play up' during the drug administration procedure, 
compared to children using the AC+ spacer. This was also reflected in the domiciliary 
setting, where children who were using the AC+ spacer exhibited significantly higher 
drug delivery consistently over the seven days, compared to the FH spacer group 
(p=0.032). In addition, the in vitro data showed that drug delivery was significantly 
dependent on age, height, weight and breathing parameters (peak inhalation flow, 
tidal volume, inhalation volume, exhalation volume, peak exhalation flow) with the 
AC+ spacer; however this was not seen with the FH spacer. Although it was expected 
that dependence on parameters such as inspiratory volume would affect day-to-day 
drug dose, it was found that drug delivery was actually better in the home setting with 
the AC+ spacer than the FH spacer. Therefore, these findings suggest that children 
interact better with a standard spacer device, such as the AC+, compared to the 
incentive FH spacer. 
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DEFINITION OF TERMS/ABBREVIATIONS 
AC+: Aerochamber Plus® spacer; a commonly used small volume paediatric spacer. 
Actuation: Activating the pMDI valve to release a predetermined dose of aerosolised 
drug particles. 
Andersen Cascade Impactor: An in vitro system designed to measure output and 
particle size distribution of aerosolised drugs; consisting of eight stages, a jet stage 
and a throat model. Each stage represents a different particle diameter fraction. 
Contrivance: Knowing how to use an inhaler/spacer device effectively but choosing 
to use it ineffectively. 
Device Compliance: Maintenance of correct pMDI-spacer technique by both the 
parent and child. 
Domiciliary setting: Home setting 
FH: Funhaler ® spacer, a novel incentive paediatric spacer ~anufactured by InfaMed, 
Australia. 
Fine Particle Fraction (FPF): The amount of drug available in particles <4. 7 Jlm in 
diameter. 
Vll 
Flow-Volume Simulator (FVS): Replicates human breathing traces by displacing air 
according to the breathing parameters of the trace. 
Mean Median Aerodynamic Diameter (MMDA): represents the diameter of the 
aerosol particles at a cumulative distribution of 50%. 
Pressurised metered dose inhaler (pMDI): (drug delivery device) - releases a 
predetermined dose of medication in an aerosol form. The drug is suspended in a 
propellant and each emitted particle contains the propellant with the drug inside. 
pMDI-spacer: Pressurised metered dose inhaler used in combination with a spacer 
device. 
Pneumotachometer: A device used to measure gas flow by converting differential 
pressure to a volumetric flow rate. 
Spacer: (drug delivery device) - a holding chamber for aerosolised drug particles; 
allows the patient to breathe tidally. Spacers usually have inhalation and exhalation 
valves. 
vm 
CHAPTERl 
INTRODUCTION 
1.1 Background to the Study 
In order to improve asthma care in the paediatric age group, it is important to isolate 
the sources of variability in drug delivery, and implement tactics to improve delivery 
of medication. Ineffective drug delivery due to poor inhaler technique is a common 
problem in young children. [1-4]; resulting in increased morbidity and greater 
number of hospital admissions [5-7]. Previous studies have shown that compliance to 
correct inhaler (pressurised metered dose inhaler- pMDI) technique ranges from 39-
68% [7-11]. Non-compliance is believed to be a result of a combination of factors 
such as poor education on asthma and treatment, poor device training, boredom and 
apathy [12-14]. 
The most commonly prescribed delivery system for young children is a pMDI with a 
valved holding spacer [2]. Accurate use of a pMDI-spacer is imperative to reduce 
dose variability and increase drug delivery into the lungs [15, 16]. Former studies 
have not previously assessed the effects of clinic-based technique training by 
integrating a qualitative analysis (check-list score) with more objective measures, 
such as drug delivery [17-20]. Furthermore, it is not only crucial to assess drug 
delivery in a clinical setting, but also outside the clinic, in a more natural setting. The 
home provides a more realistic representation of drug delivery, as opposed to the 
clinic, where the child's 'best effort' is normally measured. 
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Educating patients on asthma and the importance of achieving optimal device 
technique can be effective in adults and older children, but is less successful in young 
children [12, 19, 21], as these children cannot understand the benefits and needs of 
optimal treatment. Moreover, anti-inflammatory drugs do not provide immediate 
relief and are often delivered when the child is feeling well (symptom-free days) [2, 
22]. Consequently, this may account for the low levels of compliance and 
contrivance (knowing how to use the device effectively but choosing to use it 
ineffectively) to anti-inflammatory medication [8, 23]. Reasoning with young 
children can be very difficult [2], pmiicularly if they are under the age of five [21]. 
In an effort to address this problem a small volume paediatric incentive spacer 
(Funhaler ®; InfaMed, Australia) has been developed. The spacer includes a number 
of unique features that distract the child from the drug delivery process and provide a 
means of self-reinforcing effective inhalation technique (Figure 2.3 p. 25). The 
Funhaler ® (FH) consists of a toy arm containing a spinning disc and whistle which is 
located outside the expiratory valve of the spacer and is activated on exhalation. The 
toys perform optimally with deep tidal breathing, encouraging good technique by 
requiring the child to inhale deeply to achieve an adequate exhalation to make the 
disc spin and whistle sound. This novel device was designed to provide direct 
positive reinforcement for children on achieving effective inhalation technique [1]. 
The FH acts as an incentive for young asthmatics, making the drug delivery 
procedure more enjoyable, whilst encouraging optimal inhalation technique, 
conducive to effective asthma management. Based on a parental questionnaire, the 
FH has been shown to increase device compliance and improve inhalation technique 
in preschool children (2-6 years) over a two-week period [1]. A child's interaction 
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with the FH (compared to a standard spacer) over a longer period is not known. 
Additional evaluation, with more objective measures, is needed to verify if the 
previously observed effects of the FH are consistent. 
Furthermore, in vitro breathing simulation methods can be used to assess the effects 
of inspiratory parameters on drug delivery. The influences of individual breathing 
parameters using actual human waveforms have not been previously studied [24, 25]. 
As variability in children is so large, it is essential to analyse each breath from each 
trace separately. 
1.2 Significance of the Study 
Poor technique and device compliance remams a major problem in paediatric 
asthma, resulting in ineffective drug deli very and severe health consequences [ 1-7]. 
In order to receive the full benefits of therapy, the prescribed dose must be inhaled 
into the lungs with each administration [15, 26]. Currently, there are no published 
studies examining the effects of pMDI-spacer technique training in young children 
and their parents using a measure of drug delivery. Non-compliance to maintaining 
proper device/inhalation technique is also a key issue, especially in young children. 
The FH spacer was developed in an attempt to increase compliance to optimal 
inhalation technique [1]. 
This study assesses the effect of clinic-based technique training in children and 
parents on drug delivery. It also evaluates the way in which children interact with an 
incentive device, with prolonged use (three-nine months), and the effect this has on 
drug delivery. Lastly, the influence of age, height, weight, spacer design and 
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individual breathing parameters are examined on drug delivery using a flow-volume 
simulator. Previous studies incorporating breathing simulation methods have 
assessed drug delivery using sinusoidal waveforms only; not actual human traces 
[24, 25]. This study allows the influence of different breathing parameters to be 
examined, by using an in vitro model to simulate actual human breathing traces. 
1.3 Purpose of the Study 
This study investigates the influence of inhalation technique training, using a pMD I-
spacer, on drug delivery to preschool-age children. It also assesses if long-term use 
(three-nine months) of an incentive' device (FH spacer) increased device technique 
compliance, and improved drug delivery, compared to a standard device 
(Aerochamber Plus spacer), in a clinic setting and a domiciliary setting. Finally, the 
effects of age, height, weight, spacer design and breathing parameters on drug 
delivery are evaluated using in vitro procedures. The results from this study will be 
useful in guiding the development of strategies to improve disease management and 
the quality of life ofyoung asthmatics. 
4 
1.4 Research Questions 
1. Will education and reinforcement of correct device technique in children and their 
parents improve drug delivery? 
2. Will use of an incentive device (Funhaler spacer) improve inhalation technique 
and increase device technique compliance when compared to a standard spacer? 
3. Is drug delivery usmg an inhaler and spacer better in a domiciliary setting 
compared to a clinical setting where the child is supervised by a health professional? 
4. To what extent do breathing parameters, age, height, weight and spacer design 
affect drug delivery? 
5 
1.5 Aims 
1. To determine if drug delivery is improved by regular reinforcement of: 
-Correct use of the pMDI-spacer by parents 
- Optimal inhalation technique by preschool children 
- The use of a paediatric incentive spacer 
2. To assess intra- and inter-subject variability of drug delivery in a domiciliary 
setting in preschool-aged children. 
3. To evaluate any differences in drug delivery between a clinical setting, where the 
child is supervised by a health professional, and a domiciliary setting where the 
'white coat effect' does not exist. 
4. To evaluate the effects of: 
- Breathing parameters 
-Age 
-Height 
-Weight 
- Spacer design 
on the efficiency of drug delivery using pMDI -spacers. 
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2.1 Asthma 
2.1.1 Definition 
CHAPTER2 
LITERATURE REVIEW 
Asthma is characterised as a chronic inflammatory disease of the central and 
peripheral airways. Persistently inflamed airways become hyper-responsive [27, 28]; 
meaning that the smooth muscle around the airway is extremely sensitised, and 
exposure to an allergen can trigger an acute episode of coughing, wheezing, chest 
tightness and shortness of breath in susceptible individuals [15, 22, 26]. These 
episodes are associated with airway obstruction due to constriction and narrowing of 
the bronchioles, excessive mucus secretion and accumulation, and increased 
inflammation in the lining of the airways. If asthma is not well controlled, symptoms 
are recurrent and exacerbated at night, early in the morning, during exercise and 
when exposed to certain aeroallergens such as dust mites, animal dander, moulds, 
pollen and air pollution [4, 27, 28]. 
2.1.2 Airway Inflammation and Remodelling 
Asthma is an inflammatory disease of the airways [27, 29, 30]. This inflammatory 
response occurs due to the interaction between an allergen and an IgE antibody 
bound on the surface of a mast cell. When the allergen binds to the IgE antibody 
(antigen-antibody interaction) the mast cell is activated and starts to release 
histamine and · leukotrienes, causing smooth muscle contraction, and increased 
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vascular permeability and mucus secretion in the bronchioles of the airways [26, 31]. 
This response is immediate and starts the inflammatory cascade by attracting other 
inflammatory cells such as eosinophils, neutrophils and basophils to the site, which 
release more potent inflammatory mediators and directly contribute to the overall 
inflammation of the bronchial mucosa. This is called the late phase response and the 
process occurs within two hours to a few days [31]. The persistent inflammation 
sensitises and disrupts the lining of the airways causing airway hyper-responsiveness 
[27, 28]. 
Along with inflammation, structural changes of the airways, referred to as airway 
remodelling, occur in all patients with asthma. It is not yet known whether 
inflammation and remodelling occur independently or if inflammation is a result or 
cause of airway remodelling [28, 32-34]. Airway remodelling consists of smooth 
muscle hyperplasia and hypertrophy, sub-epithelial fibrosis, mucous and goblet cell 
hyperplasia, and epithelial detachment and regeneration. Collectively, these 
structural alterations cause thickening of the airway walls and are thought to be 
responsible for airway obstruction and hyper-responsiveness [35]. 
2.1.3 Diagnosis 
Asthma is diagnosed on the basis of family history of asthma or other atopic 
diseases, and by recognition of one or more clinical symptoms such as coughing, 
wheezing, chest tightness, and dyspnoea [3 6]. When a dramatic and apparent 
response to corticosteroids is seen a patient is said to have asthma [23]. Although 
most patients respond positively to inhaled and systemic corticosteroids, there is 
however a sub-group of patients with 'difficult to control asthma' who are 
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corticosteroid resistant. These patients respond poorly to high doses of systemic 
corticosteroids, therefore to reduce serious side-effects early detection of 
corticosteroid resistance is crucial. Studies suggest that insensitive patients may fail 
to convert the steroid to an active form, may rapidly eliminate the steroid, may have 
incomplete glucocorticoid absorption or a reduction in glucocorticoid receptor ligand 
and DNA binding affinity due to uncontrolled immune activation, possibly triggered 
by allergens or infections [3 7, 3 8]. 
Three asthma phenotypes have been identified in children: transient wheeze which 
resolves by age three, non-atopic wheeze in toddlers, and atopic wheeze where 80% 
of cases begin after six years of age [39]. If severe asthma symptoms are experienced 
during childhood it is probable that symptoms will persist into adulthood. 
Conversely, in cases of mild childhood asthma, wheezing and other symptoms are 
likely to subside before adulthood [36, 40]. Some studies propose that if asthma is 
diagnosed early in life and if treatment is initiated before six years of age, persistent 
changes in lung function may be minimised [36, 41]. However, there is some conflict 
of opinion and more research is needed in this area [ 42]. 
2.1.4 Risk Factors for Asthma 
2.1.4.1 Genetics 
Previous literature has shown that there is a significant genetic component associated 
with the development of asthma [43, 44]. A study conducted in Northern Sweden 
revealed that a person with a family history of asthma has a 3-4 fold greater risk of 
developing asthma compared to someone with no genetic history of asthma [ 45]. 
Other studies have documented that the genetic contribution to childhood asthma can 
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be as high as 75% [46, 47]. Analysis of family pedigree patterns have been shown to 
best fit with models of polygenetic or oligo genetic inheritance types, indicating that 
multiple genes may be involved in determining an individual's susceptibility to 
asthma [48]. 
2.1.4.2 Tobacco Smoke 
An active smoker has a significantly higher risk of developing asthma as an adult. A 
study conducted in Northern Sweden documented that current or ex-smokers with a 
family history of asthma have a 7-fold risk of acquiring asthma when compared to 
people who have never smoked and have no family history of asthma [ 49]. Exposure 
to tobacco smoke in utero alters the development ofthe foetal immune system which 
may predispose children to allergic diseases such as asthma [50]. In addition, tobacco 
smoke exposure during foetal growth and early childhood has been shown to 
significantly impair lung growth and lung function [51-53]. A meta-analysis study 
evaluating the influence of tobacco smoke exposure on the development of childhood 
asthma found that there was a greater risk of acquiring asthma if the parents were 
smokers [54]. 
2.1. 4. 3 Diet/Nutrition 
Changes in diet and eating habits may account for the increased rates in asthma cases 
over the last couple of decades. A current meta-analysis of 12 studies concluded that 
high body weight among school aged children increased the risk of developing 
asthma by approximately 50%. The effect of high birth weight was less distinct but 
still significant [55]. Other studies have found that children in industrialised 
countries, who consumed high levels of polyunsaturated fats and processed foods, 
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had an increased risk of developing asthma; low intake of antioxidants and fresh 
fruits was also associated with an increased risk [56, 57]. A study involving 
asthmatic children between six to seven years of age showed that an increased 
consumption of fruits and vegetables daily provided a protective effect against 
wheezing, whereas large consumption of bread, butter and margarine increased 
asthma symptoms [57, 58]. 
2.1.4.4 Allergen Exposure 
There is increasing evidence to suggest that exposure to high levels of indoor dust 
mite allergen is an important risk factor for the development of atopic sensitisation in 
children, which may facilitate the development of allergic respiratory disease [59-
61]. A large prospective study following children from birth to seven years of age 
found that high exposure to house dust mite and cat allergen significantly increased 
the development of atopic sensitisation in the first three years after birth and up to 
seven years of age. Children with a family history of atopy were much more 
susceptible to asthma with even very low levels of exposure [62]. Conversely, more 
recent studies have shown that endotoxin exposure during infancy can provide a 
beneficial guard against allergen sensitization by enhancing type 1 immunity, and 
thus reducing the risk of allergic airway disease such as asthma [63-65]. 
2.1.5 Prevalence 
Despite increased knowledge of the pathophysiology of asthma, and advances in 
treat~nent over the past several years, asthma still remains a major health issue in 
today's society [26, 66]. Asthma affects 300 million people world wide and is the 
cause of 1 in every 250 deaths worldwide [27]. Globally, the frequency of asthma is 
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greater in industrialised Western countries (i.e. Australia, New Zealand, UK) than in 
developing countries with a large rural population (i.e. Eastern Europe, India, Africa) 
[48, 67, 68]. In addition, data collected in industrialised countries over the last 40 
years has shown a significant increase in the prevalence of childhood asthma [ 48]. 
A study conducted in 2001 found that Australia has the highest prevalence of asthma 
in pre-school children, compared to other industrialised countries such as the UK, 
Canada and USA [56]. The incidence of asthma in Australia is third highest in the 
world [69, 70] and is continually rising amongst Australian-born children [71]. In a 
national health survey, parents reported asthma as the biggest health issue affecting 
their children [72]. 
2.1.6 Impact of Asthma 
Asthma can have a dramatic impact on the affected individual, their family and 
health services when the condition is not well managed. Poor symptom control leads 
to increased emergency department (ED) visits and hospitalisations, lost educational 
experiences due to school or work absence, sleep disturbance, inability to interact in 
sporting events and an overall lower quality oflife [27]. Stanford and colleagues [73] 
reported that the cost of paediatric asthma related ED visits and hospitalisations in 
1997 were approximately $157 million and $669 million respectively; these expenses 
are likely to have increased due to the rise in prevalence rates and cost of asthma 
medication. A survey conducted in New South Wales in 2001 revealed that 16% of 
children (2-12 years old) had visited an ED for an acute asthma episode over the past 
year [74]. Previous literature has also shown that children 0-4 years of age have the 
highest rates of ED attendance and hospital admissions in Australia as a result of 
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poor asthma management [69, 75]. In addition, a survey comparing a cohort of 
asthmatic and non-asthmatic children documented that overall expenditure for 
asthmatic children was 2.8 times higher than for non-asthmatic children [76]. 
It is very difficult to measure the burden of lost oppmiunities (i.e. decreased social 
activity, missed work/school days) for asthmatic people and their families. 
Collectively, people with asthma have over 100 million days of limited activity 
annually due to chronic symptoms [28]. A 2001 New South Wales health survey 
reported that 58% of children with asthma aged between 2-12 years could not 
perform normal daily activities to a 'satisfactory level in the last 12 months [74]. A 
study conducted in the United States examined the effects of sleep deprivation due to 
night time symptoms, and found that nocturnal disturbance and school absenteeism 
were closely associated. The study reported that 40% of children had experienced 
nocturnal symptoms in the previous month. During the same period, 35% of children 
were absent from school and 36% of parents reported that their child's educational 
performance decreased due to their asthma. The study also showed that if the child's 
sleep was disturbed one to three times in a month, 44% of parents missed work and if 
nocturnal wheezing had occurred on seven nights in the month, 56% missed work 
[77]. 
2.2 Asthma Treatment and Therapy 
2.2.1 Asthma Triggers 
An important aspect of treatment and symptom control is to identify specific triggers 
which exacerbate asthma symptoms. Asthma triggers can be identified through 
allergy testing. Patients should avoid exposure to these allergens by implementing 
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lifestyle and environmental changes. For example, individuals allergic to animal 
dander should remove pets from the house, and individuals with dust mite allergies 
should clean their mattresses, pillows and carpets regularly to reduce exposure [59, 
78]. However, a study of house dust mite prevention measures has shown that such 
precautions do not effectively reduce levels of exposure, and that susceptible people 
are still at risk [79]. Therefore, asthma medication must be available. 
2.2.2 Medication 
When administered correctly, effective asthma therapy is able to control the 
pathophysiological processes of asthma in most patients by reversing airway 
obstruction and managing airway inflammation [80]. The most commonly used 
medications to treat asthma include short-acting beta2 agonists, long-acting beta2 
agonists and anti-inflammatory drugs (preventer medication) [27, 28]. 
2.2.2.1 Beta2Agonists 
Short-acting beta2 agonists such as salbutamol, more commonly known as 
Vento lin®, work by enhancing bronchodilation. These medications, also referred to 
as 'rescue drugs', provide immediate relief of acute asthma symptoms by binding to 
the beta2 receptors on the smooth muscles of the bronchioles, causing them to relax 
and dilate. Symptom relief lasts up to three to four hours [4, 81, 82]. Short-acting 
beta2 agonists should only be used to relieve acute symptoms, and if required more 
than three times a week, anti-inflammatory therapy should be commenced. Long-
acting beta2 agonists such as salmeterol (Serevent ®) enhance bronchodilation over a 
longer period of time. These drugs last up to 12 hours after administration and are 
used in conjunction whh preventer/anti-inflammatory medications [ 4, 82]. 
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2.2.2.2 Corticosteroids 
Long-term therapy for chronic asthma should not be based only on 'rescue' 
medication and symptom relief. Airway inflammation is the primary cause of asthma 
symptoms, thus treatment should be focused on suppressing the inflammation with 
anti-inflammatory medications and normalising lung function. With this aim, day-to-
day asthma symptoms will be reduced and a better quality of life will be obtained 
[82-84]. Prophylactic anti-inflammatory/preventer medications can include both oral 
and inhaled corticosteroids (ICS). Oral corticosteroids have generally been replaced 
with ICS in most cases of asthma; however, they are still used in situations of acute 
asthma exacerbations where the patient is not responding to beta2 agonists [22]. 
Corticosteroids are the most potent and effective form of anti-inflammatory 
medications used to treat chronic asthma [83, 85]. Corticosteroids work by imitating 
the action of natural hormones produced by the adrenal cortex that are involved in 
regulating airway inflammation. These steroid hormones act on many cell types, 
which accounts for both their localised therapeutic effects, and unwanted systemic 
effects. Corticosteroids pass through the plasma membrane of cells and bind to the 
corticosteroid receptor in the nucleus, forming a corticosteroid-receptor complex. 
This complex can activate transcription factors or directly bind to specific DNA sites 
and alter gene expression. Through these mechanisms cmticosteroids block active 
sites of proinflammatory genes at the molecular level and regulate the release of 
molecules involved in an inflammation response at the cellular level [85-87]. 
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2.2.2.3 Inhaled Corticosteroids 
Long-term use of res has been proven to reduce airway inflammation and bronchial 
hyper-responsiveness, thereby decreasing exacerbations and the need for rescue 
drugs. [22, 88, 89]. Furthermore, it has been shown that res provide a protective 
effect in children and significantly reduce the risk of asthma-related hospitalisations 
and ED visits [90]. Commonly used ICS include: budesonide, beclomethasone 
dipropionate (BDP), triamcinolone, flunisolide and fluticasone propionate (FP) [88]. 
The different ICS drugs vary greatly in terms of topical activity and adverse local 
and systemic side effects [15, 22]. FP has the benefit of an extensive first-pass 
hepatic metabolism, which means it has a low oral bioavailability (<1 %) [86, 89, 91] 
and any drug deposited in the gastrointestinal tract is inactivated by the liver [22]. 
A new inhaled corticosteroid drug, ciclesonide (CIC), has been approved in many 
countries for use in adults and children over four years of age [2]. This novel drug 
has been designed as a 'soft steroid drug', which means it achieves high local 
concentrations to the target area with limited systemic exposure and adverse side 
effects [92]. ere is inhaled as an inactive complex and is metabolised to its active 
form in the airways [84, 93]. Once activated, ere exerts high localised anti-
inflammatory activity in the lungs, and is then rapidly metabolised and inactivated 
[92]. In addition to these pharmacokinetic benefits, CIC has a low oral bioavailability 
(1 %) and a high degree of protein binding (99%), reducing systemic activity and 
making it, at present, the safest res drug [84, 93, 94]. 
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2. 2. 2. 4 Adverse Systemic Side Effects with Inhaled Corticosteroids 
Although administering corticosteroids via inhalation is associated with fewer 
systemic side-effects compared to oral administration, the risks of adverse side-
effects are still significant with high doses of res. Thus, to reduce unwanted side-
effects the minimum effective dose for optimal symptom management should be 
used, and the amount of drug particles inhaled into the bronchiole tree of the lungs 
maximised [28, 87, 95]. Local adverse effects in both adults and children can include 
dysphonia and oropharyngeal candidiasis due to oral deposition of drug particles. 
These effects can be minimised by implementing good oral hygiene (mouth rinsing 
and gargling) after use. Other adverse side-effects include adrenal suppression and 
depletion ofbone mineral density [4, 22, 88, 93]. 
In pre-pubertal children the most concerning side-effect associated with long-term 
use of res is the impact on bone turn-over and growth. The effects on bone turn-over 
include inhibition of new bone formation and bone reabsorption. These adverse 
effects are especially troubling in children, who are acquiring bone mass quickly [ 4, 
88]. However, studies examining the effects of moderate res use (doses less than 
400 11g/day of FP or equivalent) on bone turn-over have not found a detrimental 
effect [4, 96]. 
Long-term follow-up studies have shown that growth during childhood can be 
suppressed with res use, however, this effect is short-term, and after the initial 
impact subsequent growth and final adult height are normal [4, 97-100]. Long-term 
therapy with doses of up to 200 ~-tg/day of FP or equivalent in children is considered 
to be safe, with limited risk of adverse effects. The dose response curve for 
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fluticasone propionate starts to plateau with doses above 500!-Lg/day, and at this point 
the danger of systemic side-effects is greater [88]. The risks associated with under-
treated asthma can be far greater than the risks associated with ICS use. Studies have 
shown that poor asthma management can affect final adult height severely, as well as 
cause lung hyper-expansion which can lead to significant chest deformities [1 00-
102]. 
2.2.3 Delivery Devices 
The delivery system is a vital aspect of treatment [5]. Inhalation therapy is the 
preferred and recommended alternative to oral drug administration for both adults 
and children. Inhaled aerosol medications deliver the drug directly to the affected site 
(airways); this results in a rapid therapeutic response, with a lower drug dose 
required and less systemic side effects [9, 27, 103]. There are currently three main 
types of inhalational delivery devices for children: dry powder inhalers (DPis), 
nebulisers, and pressurised metered dose inhalers (pMDis) with or without an 
attached spacer [4, 9, 104]. 
DPis are inspiratory-flow driven [22] and do not reqmre hand-mouth 
synchronisation. However, the disadvantage of DPis is that the emitted drug dose is 
dependent on the inspiratory flow of the patient. A low inspiratory flow causes the 
drug particles to impact in the mouth and throat, and as a result the lung dose is 
reduced and systemic side effects are increased [1 05]. The inspiratory force required 
to receive an appropriate dose from a DPI is generally difficult to achieve for 
children under eight years, making these devices unsuitable for children below this 
age group [2, 4, 9]. 
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The two other inhaler devices, nebulisers (Figure 2.1) and pMDis with a valved 
holding spacer, are suitable for preschool-age children and do not require 
synchronising inhalation with the release of drug [1 06, 1 07]. The pMDI-spacer 
combination is more commonly used in this age group as nebulisers are expensive, 
difficult to operate, may need an external power source, are time consuming (each 
treatment session takes up to 1 0-15 minutes) and less convenient [82, 1 06, 1 08-11 0] . 
Figure 2.1: A nebuliser with a face mask for drug inhalation and a pump 
for drug aerosolisation. 
In addition, up to 90% of the medication can be lost to the environment if the child's 
inspiratory flow does not exceed the driving flow ofthe nebuliser [109, 111]. Studies 
have also shown that nebulisers significantly increase the heart rate after treatment 
when compared to pMDis [106, 112-114], suggesting that there are greater adverse 
side-effects associated with nebulisation [115]. Furthermore, it has been shown that 
nebulisers require a much larger loading dose than pMDis to achieve the same 
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intrapulmonary delivery [91, 106, 112]. It is estimated that 2000 [lg ofFP is needed 
via a nebuliser to achieve the same effect as 300 [.tg ofFP via a pMDI [91]. 
pMDis are relatively inexpensive, portable, convenient and require less time to use 
than nebulisers [106, 112, 113]. The main problem with the use ofpMDis in children 
under the age of six years is the difficulty of synchronising inhalation with actuation 
(compressing pMDI to release drug) [22, 1 06]. However, this can be overcome with 
the use of a spacer device, which is placed in between the pMDI and child's mouth 
(Figure 2.2). A spacer provides a reservoir for the medication from which the child 
can breathe tidally, making synchroi1isation less important [104, 116]. Fmihermore, 
spacers decrease the velocity of the emitted aerosol before it enters the mouth, and 
allow the propellant around the drug to evaporate so that the inhaled particles are 
smaller and diffuse further into the lungs with decreased oropharyngeal impact [22, 
82, 104, 106, 111, 116]. 
Young children using a pMDI-spacer may need to take several breaths to clear the 
drug from the spacer [117, 118]; when larger spacers are used, the time taken to 
empty the drug from the spacer increases. Therefore, small volume spacers are the 
best option when treating young children, as they allow the drug to be inhaled from 
the spacer in a more concentrated form [116, 117, 119] before the particles 
agglomerate and are lost due to sedimentation [2]. 
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Figure 2.2: A child using a pMDI with an Aerochamber Plus® spacer. 
One of the problems with plastic spacers is that they can become electrostatically 
charged on the inside, causing the drug particles to adhere to the spacer wall, and 
thus compromising drug output [116, 120]. However, this problem can be overcome 
by coating the inside of the spacer with ionic detergent [118]. Detergent coating of 
spacers has been shown to significantly reduce electrostatic charge and increase drug 
delivery by up to 46-71% [121]. 
2.3 Factors Affecting Drug Delivery 
2.3.1 Age, Height and Ventilatory Parameters 
There are many factors which affect drug delivery in children, including age, height 
and breathing parameters such as tidal volume, peak inspiratory flow and inspiratory 
volume [116, 119, 122]. 
2. 3.1.1 Breathing Simulation 
The influence of age, height, weight and breathing parameters on drug delivery can 
be studied in vitro using a flow-volume simulator (FVS). Pre-recorded human 
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breathing traces can be simulated through a flow-volume simulator to replicate the 
patient's actual breathing pattern. The delivered dose of drug that would have been 
inhaled by the patient is captured on an inspiratory filter inserted between the drug 
delivery device (pMDI-spacer) and the breathing simulator [123]. While in vivo filter 
data can be correlated with markers of increasing lung size (age, height, and weight) 
the FVS can be utilised to examine the effects of individual inspiratory parameters, 
for example lag time, inspiratory volume and inspiratory flow. 
Previous studies using breathing simulation methods have incorporated sinusoidal 
and square waveforms instead of aCtual human patterns. Investigators have created 
sine and square waveforms using the average measure for each breathing parameter 
(tidal volume, peak inspiratory flow, breathing frequency and inspiratory duty cycle) 
from several regular breathing traces [24, 25]. This method of investigation reduces 
the variability which is found from breath to breath and patient to patient, especially 
in children. As intra- and inter-variability is high in children it is vital to incorporate 
the actual trace for each patient and analyse each breath separately. 
2.3 .2 Technique, Training and Education 
Incorrect use of inhaler devices significantly compromises drug delivery and 
increases adverse side-effects [5-7]. In order to achieve the full benefits of treatment, 
competent administration is essential [15, 26, 124]. Incorrect pMDI technique is 
common among many patients, including adults [125-128], but especially young 
chndren [129, 130]. Therefore, training and technique assessment by a health 
professional is crucial [5, 6, 19, 20, 125]. A study of 55 asthmatic children showed 
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that only 73% had a near correct technique that allowed any drug to enter the lungs 
[7]. 
In young children, the parent is responsible for administering the medication [ 131]; 
therefore the parent must be taught how to use the device correctly, and the child 
how to perform the optimal breathing manoeuvre [21]. The most common errors 
parents make when administering inhaled therapy include: not shaking the pMDI 
canister before actuating, not allowing five breaths to be completed before re-
actuating and not co-ordinating actuation with the start of inhalation. Errors made by 
young children include: failure to keep their mouth tight over the mouthpiece of the 
spacer to stop the drug from escaping, inability to inhale the drug slowly and deeply 
to minimise impaction of particles in the proximal airways, breathing from the nose 
instead of the mouth, and forgetting to breath-hold after inhalation to maximise 
sedimentation of particles [103, 129, 132]. Previous studies suggest that the most 
beneficial form of education for adults and older children is one which includes both 
verbal counselling and a physical demonstration [133]; written instructions alone are 
not an effective measure [134, 135]. Toddlers learn by imitation and repetition, 
therefore video demonstrations or role-playing situations can be effective teaching 
methods [18]. 
Caregivers and patients who receive repeated training sessions are more likely to 
display competency in device implementation technique when compared to patients 
with no training [18, 19]. Kamps and colleagues [18] demonstrated that only 57% of 
children had correct technique after one training session and 98% after three 
sessions. In order to ensure the device is continually used effectively, monitoring and 
reinforcement is needed [19, 135, 136]. A previous study found that after patients 
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had established effective skills, only half continued to use the pMDI effectively in 
the 1-30 days following the official training session [137]. 
Contrivance (knowing how to use the device effectively but choosing to use it 
ineffectively) is also a problem in paediatric asthma [8, 23]. Education and strong 
communication between the physician and parent/guardian is a crucial determinant 
of therapeutic success [22, 131, 138, 139]. If the parent does not see their child's 
asthma as a severe health problem due to lack of knowledge about the condition, it is 
likely that device compliance will be poor [28, 140, 141]. The aim of healthcare 
providers is to impart the importance of correct device teclmique, and continuous 
anti-inflammatory treatment, in order to attain better asthma control, reduce 
exacerbations and reduce the need for aggressive interventions [28, 142]. Education 
is an integral pmi of asthma management as it provides patients and their families 
with a greater understanding of asthma, device implementation skills (and the 
impmiance of device compliance), and emergency behaviours, leading to better 
symptom control and thus reducing associated morbidity [28, 143]. However, whilst 
education is an effective method for increasing co-operation in older children and 
parents, it is not so effective in young children, particularly if they are under the age 
of five where reasoning can be very difficult [12, 19, 21]. 
2.3 .3 Device Compliance 
In an attempt to address the issue of device technique compliance in young asthmatic 
children, an incentive spacer, the "Funhaler" (Funhaler®; InfaMed, Australia), has 
beeri developed (Figure 2.3). The spacer features a toy arm with a disc and whistle, 
so that when the child breathes deeply the disc spins and a whistle sound is created. 
The incentive toy encourages good technique (deep tidal breathing) and does not 
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interfere with delivery of medication, as it is separated from the main inspiratory 
route. The Funhaler (FH) is designed to address the needs of young asthmatic 
patients by making the delivery process more enjoyable and less boring in an attempt 
to increase device technique compliance. A two week preliminary study, based on a 
parental questionnaire, revealed that compliance in children (2-6 years of age) 
increased with the FH when compared to a standard spacer. However, the long-term 
effects of such an incentive device are not yet known [ 1] . 
Figure 2.3: Funhaler Spacer®. A: Parts of the Funhaler spacer. B: A 4-year-old 
child using the Funhaler spacer with a face mask. 
2.4 Conclusion 
From the review of literature it is apparent that there are many factors that can 
influence drug delivery in young children; incorrect inhaler technique, the child's 
breathing parameters, contrivance and device compliance. The effect of inhaler 
technique training in preschool children (2-6 years) and their parents has not been 
extensively examined before. Previous studies have found that training improves 
.·. 
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technique, however their results have been based on subjective measures, namely 
check-list analysis [17-19, 135]. Therefore, more objective methods of assessment 
are needed to conclusively evaluate the effects of inhaler training. Furthermore, the 
effect of clinic-based technique training on drug delivery in the home has not been 
examined. The home provides a more realistic representation of drug delivery as 
there is no clinical supervision and the child is in a more comfortable environment. 
Therefore, in addition to clinic-based training, this project assesses drug delivery in 
the home. 
A preliminary study, based on a parental questionnaire, has indicated that the 
Funhaler ® design improves device technique compliance in pre-school aged children 
(2-6 years) over short-term (two week) use [1]. This project examines the long-tern 
effects of the FH, with more objective measures, on the common problem of device 
compliance. 
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CHAPTER3 
MATERIALS AND METHODS 
3.1 Materials 
3 .1.1 Chemicals/Drugs 
Methanol (Lab-Scan HPLC grade) 
Sodium Hydroxide (NaOH) (Sigma, USA) 
Liquid salbutamol Chemical Reference Standard (Glaxo, USA) 
Salbutamol pMDI (1 001Jg/actuation, Vento lin®) 
3 .1.2 Equipment 
Inspiratory Filters (Hydrophobic membrane Uni-Filter Junior Datex-Ohmeda) 
Aerochamber Plus Spacer® (AC+; Trudell Medical International, Canada, 135ml) 
Funhaler Spacer® (FH; InfaMed, Australia, 225 ml) 
Flow-Volume Simulator (Series 1120 Hans Rudolph, Kansas, USA) 
Pneumotachometer (RSS 100 Hans Rudolph, Kansas, USA) 
UV Spectrophotometer (UV -1601, Shimadzu Scientific, Japan) 
Bu~hner flask 
Reticulated vacuum/suction system 
Digital Video Camera (Canon 2.0 Mega Pixels MVX3i) 
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Flow Chamber Perspex Box 
lL Calibration Syringe (Koko, Pulmonary Data Service Instrumentation) 
Andersen Cascade Impactor (ACI; Andersen Instruments, USA) 
Vitalograph (Model DFM2, Copley Scientific, UK) 
3.2 Study Population 
Ethical approval for this study was obtained from Princess Margaret Hospital Ethics 
Committee (Registration No. 933/EP) and the Human Ethics Sub-Committee Faculty 
of Computing Health and Science, Edith Cowan University, Joondalup. 
The study involved a cohort of 47 children between 2.5-7.5 years of age with mild, 
stable asthma who were on daily inhaled anti-inflammatory medication (fluticasone 
propionate) and did not suffer from any other lung disorders. The 47 patients were 
recruited from a larger trial (Funhaler Trial) which is cunently being undertaken at 
Princess Margaret Hospital for Children in Perth, Australia. The trial involves 
monitoring asthma symptoms and compliance therapy in children using either an 
® ® Aerochamber Plus (AC+; Trudell Medical International, Canada) or a Funhaler 
(FH; InfaMed, Australia) spacer device, over a 12 month period. Of the 47 patients in 
the present study, 24 were part of the AC+ spacer group (15 male, mean age 63.7 
months, range 30-90 months), and 23 were part of the FH (14 male, mean age 60.5 
months, range 36-90 months). Four children (AC+: n=2, FH: n=2), with a mean age 
of 51 months (36-60 months) were identified as nose breathers. These children were 
analysed as a separate group. All patients had used either the AC+ or FH for a period 
of three to nine months (depending on the number of visits they had previously 
attended for the. }{unhaler Trial). The participants' parents or caregivers were 
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provided with both verbal and written information regarding the study on their 
regular attendance for the Funhaler Trial. Parents were assured they were free to 
refuse participation or withdraw their child from the study without prejudice to future 
asthma care. On agreement to take part in the study parents were asked to sign an 
informed consent (Appendix I p. 87) on their child's behalf. 
3.3 Study Design 
The present project was divided into three categories: clinic visit, domiciliary filter 
study and in vitro procedures (Figure 3.1 ). 
3.3 .1 Clinic Visit 
3.3.1.1 Spacer Technique Evaluation and Training 
Initially parents and children attended a clinic visit where two filter studies were 
performed. The first study involved a pre-training filter analysis. The parent was 
asked to administer five single actuations of pMDI salbutamol (100~-Lg/actuation, 
Ventolin ®) while the child breathed for five tidal breaths in between each actuation, 
using the technique normally employed at home. Each child used the spacer he/she 
was randomised to. Salbutamol was captured on a low resistance inspiratory filter 
(Uni-Filter Junior Datex-Ohmeda) with a minimum dead volume (<50ml), which 
was placed between the child's mouth and their spacer (Figure 3.2 & 3.3). The 
aerosol was drawn onto the filter- the child did not inhale any drug into their body. 
Both the parent and child were video-recorded (using a digital camera which was 
connected to a desk top computer containing a multi media software program) in 
their attempt to use the device optimally. As part of the clinic training process, the 
technique employe~ by both the parent and child was assessed according to a 
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criterion checklist (pre-training evaluation; Appendix II p. 91), and any errors in the 
parent's administration technique and the child's inspiration technique were 
corrected by physical demonstration and verbal instructions. 
The number of training sessions the parent and child had received prior to their clinic 
visit for the present study was dependent on the number of visits they had previously 
attended for the Funhaler Trial. Children who were recruited at visits one, two and 
three had received one, two or three training sessions, respectively, before 
recruitment into this sub-study. 
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CLINIC VISIT 
>- Pre-training filter study 
>- Evaluation of administration 
procedure and technique training 
(both parent and child) 
>- Post-training filter study 
>- Breathing trace recorded (for in 
vitro evaluation) 
>- Domiciliary materials provided 
Analysis of drug delivery on pre and post 
training filters (2 samples collected per 
child): evaluation of the effects 
administration technique training on drug 
delivery in a clinical setting. 
D 
IN VITRO METHODS 
>- Breathing pattern transferred to a 
FVS 
);> Filter placed between FVS and spacer 
device (FVS represents child in vitro) 
);> Administration procedure mimicked 
the clinic and domiciliary filter 
studies 
);> All measurements were taken in 
duplicates 
);> Measurement of breathing parameters 
Analysis of drug delivery using a FVS: 
evaluation of the effects of age, height, weight 
and breathing parameters on drug delivery. 
DOMICILIARY 
>- Performed in the child's home 
with no study supervisor 
>- Administration and filter set-up 
was identical to the clinic filter 
studies 
>- A new filter will be used every 
morning and evening 
>- Filters were collected at the end 
of the 1 week period from the 
child's home 
Analysis of drug delivery over a 1 week 
period (morning and evening- 14 
samples collected per child): evaluation 
of variability in drug delivery in a home 
setting. 
Figure 3.1: Study design. The project was conducted m three areas: clinic visit, 
domiciliary filter study and in vitro procedures. 
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Figure 3.2: Funhaler spacer attached to a filter. Aerosolised drug is collected on the 
inspiratory filter, so the child does not inhale any drug. 
Figure 3.3: Aerochamber Plus spacer attached to a filter with an adaptor. 
Aerosolised drug is collect on the inspiratory filter, so the child does not inhale any 
drug. 
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Subsequently, both the parent and child were asked to watch a one minute 
educational video featuring either the FH or AC+ spacer, depending on which device 
the child was randomised to. The FH children did not see the AC+ video and vice 
versa, however, both videos showed the same caregiver administering medication 
and the same child performing the breathing manoeuvre. The video demonstrated the 
optimal breathing technique to be performed by the child (deep slow breathing, five 
tidal breaths after each actuation) and correct use of a pMDI-spacer by the parent 
(shaking. the canister before each actuation, allowing five tidal breaths before re-
actuating). The video also contained information on how to clean the spacer and 
reduce electrostatic charge by detergent coating. Once the training session was 
completed a post-training filter analysis was conducted. The same administration 
procedure was performed as with the pre-training filter study. The parents and 
children were video-recorded again and their technique was re-assessed (post-
training evaluation; Appendix II p. 91). The effects of training were analysed by 
comparison of the pre- and post-training videos and technique scores (qualitatively) 
and the total drug recovered on the pre- and post-inspiratory filters (quantitatively; 
see section 3.4.1 pg. 44). 
3.3.1.2 Breathing Recording 
Breathing patterns were recorded for all study subjects during the clinic visit using a 
custom-built transparent flow chamber consisting of a Perspex box and a paediatric 
pneumotachometer (RSS 100 Hans Rudolph, Kansas, USA). The flow chamber 
enclosed a small volume spacer and a pMDI (Figure 3.4). These devices were held in 
position by a special sleeve fitting located on the floor of the box. The front of the 
Perspex box contained an opening allowing only the mouthpiece of the spacer to 
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protrude whilst keeping the exhalation valves of the spacer inside the box. The roof 
and the side of the box also contained small openings. The opening on the side 
allowed a bias flow of medical air to enter the box via a tube. Medical air was 
introduced at a constant flow rate of approximately 4 Llmin in order to prevent the 
accumulation of carbon dioxide in the box from exhaled air. The pneumotachometer 
was placed in the opening on the roof of the flow chamber to record the child's 
breathing pattern. The air flow through the two spacer devices is shown in figure 3.5. 
Figure 3.4: Custom built flow chamber used to record breathing patterns in children 
using either the Aerochamber Plus (pictured) or Funhaler. 
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Figure 3.5: A: Air entrainment through the Aerochamber Plus spacer. B: Air 
entrainment through the Funhaler spacer. Green arrows represent inhalation flow 
and red arrows represent exhalation flow. 
The flow chamber was kept air tight during the recording procedure and changes in 
air pressure (air inhaled and exhaled through the spacer) were measured through the 
membrane in the pneumotachometer. The pneumotachometer was connected to a 
desk top computer which held the controlling software (Research Pneumotach 
System, KORR Medical Technologies; Windows Software Version 3.07b), designed 
to record breathing traces. Before each recording the pneumotachometer was 
calibrated with a lL syringe (Koko, Pulmonary Data Service Instrumentation) and 
the temperature and humidity in the clinic room was recorded. Each patient was 
administered one actuation of a placebo pMDI via an actuation port on the flow 
chamber at the start of inhalation and was asked to breathe for ten tidal breaths 
through the spacer whilst their breathing pattern was recoded. Each trace was 
digitally recorded at a flow range of 0-1 OOL/min at 50Hz via a computer and was 
stored in a RSS (Really Simple Syndication) file format. 
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All breathing traces were recorded using the spacer type the study subject was 
randomised to. A clean detergent coated spacer (Anionic Detergent: Liquid Pyroneg, 
Diversey, Australia) was used for each new recording. To keep the procedure as 
natural as possible for the child, the flow chamber was designed to ensure minimal 
difference in the child's normal drug administration experience. The breathing 
pattern from each subject was later simulated in vitro using a Flow-Volume 
Simulator (FVS) (see section 3.3.3.2 pg. 39). 
3.3.2 Domiciliary Filter Study 
At the end of the clinic session parents were provided with all the materials needed to 
perform the domiciliary filter study (instruction sheet, 14 inspiratory filters, a new 
salbutamol pMDI, filter labels and a storage box). 
The domiciliary study was completed by the parent and child in their home, without 
supervision from the researcher (JM). The filter-inhalation set-up and technique 
required to perform the study was demonstrated to the parentis at the clinic visit by 
the researcher and a take-home instruction sheet with diagrams was also provided. 
Two filter set-up systems were used in this study, depending on which spacer type 
the child was randomised to (Figure 3.2 & 3.3 pg. 32). 
The filter set-up and administration procedure was identical to the pre- and post-
training filter studies performed in the clinic. The aerosolised drug was collected on 
an inspiratory filter that was placed between the child's mouth and their spacer - the 
child did not inhale any drug into their body. When the salbutamol pMDI 
(lOOJ.!glactuation, Ventolin ®) was actuated the quantity of drug which would 
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normally be inhaled is deposited on the filter; this equates to the 'total body dose' of 
drug which would have been inhaled by the child. The domiciliary study was 
performed using the filters provided and the study medication for a period of one 
week, after every normal routine administration of anti-inflammatory medication 
(normally taken twice daily- morning and evening). Parents were asked to administer 
five single actuations of salbutamol (shaking the pMDI before each actuation), while 
the child took five tidal breaths from the spacer in synchronization with each 
actuation. Before each administration, parents attached a new filter to the spacer, thus 
14 samples were collected (two samples per day) for each child. After each filter was 
completed parents were asked to wrap the filter in aluminium foil and store it in the 
box provided until all filters were completed and collected from their home by the 
researcher. Each filter was identified by an adhesive label affixed by the parent, 
detailing filter number and time of day (am/pm). 
This section of the study assessed daily variability of drug delivery in a more natural 
setting. The home filters provide a more realistic representation of the total drug 
administered as the delivery process takes place in the child's natural environment. 
The child's regular medication regimen was not interfered with during the study as 
the filter process took place after every prescribed administration and no additional 
medication was inhaled. 
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3.3.3 In Vitro Procedures 
3.3.3.1 Waveform Conversion 
Each original recorded breathing trace stored in a RSS file format was converted to a 
FVW file format for compatibility with the FVS. Breathing traces were converted 
using a waveform conversion program (RSS Waveform Editor, Hans Rudolph). The 
program was able to subtract the bias flow (in Lisee) from the waveform which was 
introduced during the recording. The same program was used to digitally cut the first 
five consecutive breaths from each ten-breath breathing trace. The first five breaths 
were used to keep all in vivo and in vitro procedures consistent (Figure 3.6). 
100~----------------------------------~ 
"C 
c 
0 
(.) 
50 
Exhalation 
~ 0 -~~,---~~--r-----~--nL--.-~~4-.---~--~----~1 
-UJ 
Q) 
.... 
-
·-:--50 
(.) 
Q) 
"C 
3:-100 
0 
LL 
1 2 3 
/ 
Inhalation 
4 5 9 10 1 
-150 -l.....-------------------------------------1 
Time (seconds) 
Figure 3.6: A representative five-breath breathing trace. Negative flow represents 
inhalation and positive flow represents exhalation. 
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3.3.3.2 Breathing Simulation 
All recorded breathing traces from each child were simulated through a Flow-
Volume Simulator (FVS) (Series 1120 Hans Rudolph, Kansas, USA). A FVS is a 
computer-controlled device consisting of a cylindrical piston which displaces air 
according to the recorded breathing parameters of each breathing trace. An 
inspiratory filter was placed between the breathing simulator and the spacer to 
capture the delivered drug (Figure 3.7). The quantity of drug on the filter represented 
the 'total body dose' of particles inhaled by the child. As with the clinic and 
domiciliary filter studies, a total of five separate actuations of pMDI salbutamol 
(100!-lg/actuation, Ventolin ®)were delivered into the spacer. After each actuation the 
five-breath trace was simulated to 'inhale' the drug (salbutamol was actuated 
simultaneously with the start of inhalation). The salbutamol pMDI was shaken 
thoroughly before each actuation. For each breathing trace the procedure was 
repeated to obtain duplicate measurements. All inspiratory filters, spacers and 
actuators were assayed as detailed in section 3 .4 .1. 
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Differences in the ambient conditions between the time of recording and the time of 
simulation can alter the flow volumes, therefore before each· simulation the 
temperature and humidity of the room was entered into the FVS program which 
automatically corrected for any differences. Furthermore, prior to use, all spacers 
were detergent coated in a 1:125 dilution of ionic detergent (Liquid Pyroneg, 
Diversey, Australia) for 30 minutes and left to drip dry for 24 hours to diminish 
electrostatic charge. The weight of the canister was measured before and after every 
trial. The canister was disposed of at a weight of approximately 15g as doses become 
more unpredictable after this weight. 
3.3.3.3 Validation of the Flow-Volume Simulator 
The use of a breathing simulator is based on the assumption that it will accurately 
simulate a real-life human breathing trace and show a correlation between in vivo and 
in vitro drug delivery. Therefore, an important part of this project was to validate 
whether the FVS was able to replicate an in vivo measurement of drug dose. Eighteen 
breathing traces from healthy adult subjects (40% male) aged 21-32 years (mean age 
25) were recorded using a transparent flow chamber (the same flow chamber was 
used to record the study subjects breathing patterns at the clinic visits) whilst in vivo 
drug filter samples were taken. The airtight flow chamber contained a small volume 
spacer (AC+) for measurement of in vivo drug delivery and a pneumotachometer to 
record the subject's inspiratory parameters. Five individual actuations of pMDI 
salbutamol were delivered into the spacer. Before each actuation the pMDI was 
shaken vigorously and the subject's breathing trace was recorded (i.e. a total of five 
breathing traces were recorded per subject). Salbutamol was captured on an 
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inspiratory filter placed between the spacer and the subject's mouth (one filter was 
used per subject). 
In order for the FVS to recognise the breathing traces, each original recording was 
converted from an RSS file to a FVW file format where the bias flow was subtracted 
from the waveform. The breathing traces were then transferred to the FVS (FVS 
represents the subject in vitro). An inspiratory filter was placed between the FVS and 
the AC+ spacer to capture the drug. As with the breathing recording procedure a total 
of five actuations of pMDI salbutamol were administered into the spacer device 
individually. With each actuation the pMDI was shaken and the five separate 
breathing traces for each subject were simulated in order of recording. One filter was 
used per subject (i.e. for all five actuations and five breaths). All inspiratory filters 
were analysed as detailed in section 3.4.1. There was a significant correlation 
between in vivo and in vitro drug measurements (Figure 3.8). 
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Figure3.8: A regression line showing the mean and ± 1.96 SD ofFVS drug dose (in 
vitro) vs. in vivo drug dose. There was a significant correlation (r2= 0.85, p<O.OOl) 
between the two measurements of drug delivery. 
3. 3. 3. 4 Measurement of Breathing Parameters 
The breathing parameters were measured for each recorded waveform. The original 
(RSS file format) breathing trace was converted to a SIG file format using the 
software that was initially used to record the breathing trace. The data from each 
original waveform was then displayed and the bias flow (Lim) was removed. Each 
breath from each waveform was analysed separately using a custom made software 
program (Breathing Simulation Calculation- BSC; Programmer: Brad Zhang, 
Princess Margaret Hospital) on the following breathing parameters: tidal volume, 
inhalation volume, inhalation time, exhalation volume, exhalation time, peak 
inhalation flow, time to peak inhale, peak exhalation flow and time to peak exhale. 
The influence of these breathing parameters, age, height and weight were assessed on 
drug delivery. 
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3.4 Drug Analysis 
3.4.1 Drug Recovery 
Aerosolised salbutamol was recovered from inspiratory filters , actuators and spacers 
using HPLC grade methanol. NaOH (0.1M) was added to all samples to increase the 
absorbance sensitivity, and salbutamol was quantified using an ultraviolet (UV) 
spectrophotometric method. To wash the filters , each filter was placed over the neck 
of a Buchner flask, which was connected to a vacuum. Methanol was drawn through 
the filter membrane, and collected in the flask. The solution was transferred into a 50 
ml volumetric flask containing 5 ml ofNaOH, and methanol added to achieve a final 
volume of 50 ml. Actuators used during the breathing simulation procedure were 
washed with methanol into 25 ml volumetric flaks, each containing 2.5 ml ofNaOH. 
Methanol was added to achieve a final volume of 25 ml. Spacers were washed twice; 
methanol from each wash was transfened to two separate 50 ml volumetric flasks 
with 5 ml NaOH, and methanol added to make a final volume of 50 ml. 
The salbutamol content of all samples was determined using a UV spectrophotometer 
(UV -1601, Shimadzu Scientific, Japan) at an optical wavelength of 246 nm, which 
has been established from a calibrated analysis. All absorbance measures were 
performed in duplicate and the mean for each was calculated. A five-point standard 
curve was prepared each day using chemical reference salbutamol, with 
concentration doses of 0.2, 0.5, 1.0, 1.5 and 2.0 1-tg/ml. Each standard contained a 
10% (v/v) 0.1 M NaOH. Standard curves were linear within the concentration range 
of 0.2 to 2.0 1-lg/ml. Methanol containing 10% (v/v) 0.1 M NaOH was used as a blank. 
The amount of salbutamol in each sample was calculated (using the mean absorbance 
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measure) from the standard curve that was prepared at the time the sample was 
measured. The standard deviation and %CV for each sample was also calculated. 
3.4.2 Validation ofMethod of Drug Recovery from Inspiratory Filters 
The method of recovery and assay of salbutamol from inspiratory filters was 
validated by placing a known amount of salbutamol on the filter membrane, then 
extracting and analysing the amount of drug retrieved from the filter. Three different 
doses of salbutamol were used: low (12.5 1-1-g), medium (50 1-1-g) and high (1250 1-1-g), 
and each dose was tested in triplicate. Filters were assayed as detailed in section 
3.4.1. The mean (range) absolute dose and proportion of drug recovered is shown in 
Table 3.1. 
Table 3.1: Validation filter results performed with salbutamol. The mean drug 
recovered from the three repeats; expressed in absolute values and as a percentage 
(%)(range). The standard deviation and percent coefficient of variance (%CV) also 
shown for each dose. 
Mean Dose 
Dose (IJ9) Recovered (IJg) Mean% Recovery STDEV %CV 
25.0 1-19 24.86 99.43 (98.3-100.6) 1.18 1.18 
50.0 IJQ 49.75 99.49 (99.1-1 00.3) 0.68 0.68 
250 1-19 243.07 98.23 (96.8-97.4) 0.34 0.35 
3.4.3 Actuator Validation 
Inconsistent dosing can be caused by differences in actuator moulds. Moulding can 
vary from batch to batch; therefore it is important to test different actuator batches 
for variable dosing. An Andersen Cascade Impactor (ACI; Andersen Instruments, 
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USA), consisting of eight stages, a jet stage and a throat model (Figme 3.9), was 
used to test six randomly selected actuators. Each stage of the ACI represents a 
different particle size fraction with cut-off diameters of 9.0, 5.8, 4.7, 3.3, 2.1, 1.1 , 
0.7, 0.4 and 0 f.!m. The patiicle size distribution was calculated by evaluation of drug 
impaction on each stage of the ACI. The fine particle fraction (FPF) corresponds to 
the amount of drug available in particles <4.7 f.!m in diameter, and are most likely to 
deposit in the lung. The mass median aerodynamic diameter (MMAD) of an aerosol 
examines the aerodynamic behaviour of the patiicles. The MMAD represents the 
diameter of the aerosol particles at a cumulative distribution of 50%. 
Each actuator was adapted to the throat of the ACI; ten actuations of salbutamol 
pMDI were dispensed into the ACI in total (the pMDI canister was shaken for ten 
seconds between each actuation), while a constant flow of 28.3 Llminute was drawn 
through the ACI via a pump. The flow was calibrated using a digital flow meter 
(Vitalograph; Model DFM2, Copley Scientific, UK). All components of the ACI and 
actuator were washed separately with methanol in 25 ml volumetric flasks; the drug 
content was assayed using a UV spectrophotometer as detailed in section 3.4.1. The 
drug output from each actuator was calculated by analysis of drug particle impaction 
on each stage, the throat and actuator. There was minimal difference in drug output 
between the individual actuators. These results are summarised in table 3.2 and 
figure 3.1 0. 
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Figure 3.9: An Andersen Cascade Impactor; consists of a throat, jet-stage, 
eight-stages and a pump port. Broken arrows represent the flow direction at 
28.3 Llmin. 
Table 3.2: The total recovery, total exiting actuator, particles exiting actuator with 
<4. 7 ~-tm shown in absolute values (~-tg) and percent of total recovery shown for each 
actuator. Mass median aerodynamic diameter (MMDA) also shown for each 
actuator. There were small discrepancies between the individual actuators. 
Total Exiting T9tal Exiting 
Total exiting actuator exiting actuator 
recovery actuator <4.7J,Jm actuator <4.7J,Jm MMAD 
Actuator (J,Jg) (J,Ig) (J,Jg) (%) (%) (J,Jm) 
1 93.2 78.2 23.1 83.9 24.8 3.3 
2 91 .6 78.6 21.7 85.8 23.7 3.2 
3 92.7 82.9 19.4 89.5 20.9 2.9 
4 · 92.7 81.3 24.0 87.7 25.9 2.9 
5 91 .3 78.5 23.4 85.9 25.7 2.8 
6 92.7 79.3 25.6 85.6 27.6 3.0 
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Figure 3.10: The cumulative distribution (%) and particle diameter (!lm) for each 
actuator tested. There were minimal differences between the six actuators tested. 
3.5 Data Analysis 
All statistical analyses were completed using SPSS software program (Version 12). 
A statistician was also consulted to confirm that all analyses were conducted 
appropriately. All filter doses were expressed as the amount (!lg) of drug deposited 
on the filter per 100 Jlg actuation. Nose breathers were excluded from all analyses 
and were assessed as a separate group. The effect of immediate training was assessed 
by a two-way analysis of variance (ANOV A). Spacer type (AC+ I FH) was analysed 
as a between subject factor, and the clinic training filters (pre and post) as within 
subject factors. In addition, a one-way ANOVA was also performed to assess the 
effect of repeated training on drug delivery by comparison of post-training filter 
doses with the number of training sessions. 
48 
The mean and standard deviation (SD) was calculated for each of the 14 domiciliary 
filters collected from each child. The effect of any significant differences in drug 
delivery in the domiciliary setting was assessed using a three-way ANOV A, 
comparing spacer type (AC+ I FH) with day (1-7 days) and time of day (am/pm). A 
two-way ANOV A was also used to evaluate if there were any significant differences 
in drug delivery between the domiciliary setting and clinic setting. Spacer type was 
used as a between subject factor and the average of the 14 domiciliary filters were 
compared with the clinic post-training filter as within subject factors. A generalised 
estimating equation with robust standard errors (weighted analysis) was also 
performed to validate whether the difference in filter samples between the clinic and 
home setting influenced the results . Fmihermore, an independent t-test was used to 
compare the age distribution between the two spacer groups in order to validate if 
age was a confounding factor for any of the between subject comparisons. 
Coefficient of variance was used to assess intra- and inter- technique variability for 
the FVS analysis. Regression analyses were performed to examine the effects of age, 
height, weight and ce1iain breathing parameter (tidal volume, inhalation volume, 
inhalation time, exhalation volume, exhalation time, peak inhalation flow, time to 
peak inhale, peak exhalation flow and time to peak exhale) on drug delivery. 
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CHAPTER4 
RESULTS 
This project was divided into three major categories evaluating the effects of in vivo 
device technique training, in vivo drug delivery in the domiciliary setting and the 
influence of age, height, weight and different breathing parameters on in vitro drug 
delivery. 
4.1 Study Population 
The demographics of the study population for this project are summarised in table 
4.1. A total of 47 children, 24 of whom were allocated to the FH arm and 23 to the 
AC+ arm, attended a clinic session and underwent drug delivery assessment and 
training. Of the 4 7 children recruited, four were analysed separately as these children 
were identified as nose breathers (Table 4.1; nose breathers), and an additional two 
withdrew from the domiciliary study after the clinic session was completed. Reasons 
for withdrawal were non-compliance (n=1; FH) and the child's daily anti-
inflammatory medication being discontinued (n=1; AC+). All study participants were 
similarly distributed for age and gender between the AC+ group and the FH group 
(Table 4.1) . 
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Table 4.1: The study population; the mean age (range), gender (percent male) and 
the spacer used (percent male) of children who attended the clinic session, 
participated in the domiciliary study and were identified as nose breathers. There 
were no significant differences in age and gender between the AC+ group and the FH 
group. 
AC+ Spacer FH Spacer p-value 
Clinic Session (n=43) Age (Months) 65.76 (42-90) 60.50 (36-90) p>0.05 
Gender 33% Male 33% Male p>0.05 
Domiciliary Study (n=41) Age (Months) 66.95 (46-90) 61.33 (36-90) p>0.05 
Gender 33% Male 33% Male p>0.05 
Nose Breathers (n=4) Age (Months) 45 (30-60) 57.5 (55-60) p>0.05 
Gender 25% Male 25% Male p>0.05 
4.2 Clinic-Based Technique Training 
The effect of clinic-based training in pMDI administration and inhalation technique 
was assessed on drug delivery in this section of the study. 
In an overall analysis, the pre-training filter had a higher mean drug dose compared 
to the post-training filter, however the magnitude of difference did not reach 
statistical significance (p=0.078). There were no significant differences in technique 
scores between the pre- and post- training assessments. Also, the type of spacer used 
(AC+ or FH) had no significant effect on the filter doses (p=0.213). Furthermore, no 
significant differences were found between the pre- and post- filters within the same 
spacer group (AC+ p=0.483, FH p=O.l 05) (Figure 4.1 ). Finally, repeated training did 
not result in a significant difference in drug delivery (p=0.151). However, there was 
a significant difference in pMDI administration and inhalation technique scores at the 
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baseline visit compared to visits 2 and 3 (p<O.OOl), but not compared to visit 1 
(p>0.05) (Table 4.2). 
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Figure 4.1: Drug dose (±SD) on the pre and post-training filters within the AC+ and 
FH spacer groups. The decrease in dose between the pre and post filter was greater in 
the FH group, but this decrease was not significant. 
Table 4.2: Baseline and post-training clinic scores (% of skills performed correctly). 
There was no significant difference in training scores between baseline and visit one. 
There was a significant difference between baseline scores and visits three and four. 
Number of Clinic Baseline Post-Training 
Visits Score(%) Score(%) p-value 
1 (n=15) 83.9 89.6 p>0.05 
2 (n=13) 79.7 94.1 p<0.001 
3 (n=15) 77.4 93.9 p<0.001 
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4.2.1 Nasal Inhalation 
A total of four children, with a mean age 51 months (rarige 30-60 months) were 
recognised as nose breathers from both spacer groups (AC+: n=2, FH: n=2). These 
children were excluded from the overall analyses and were studied as a separate 
group. The mean of the pre- and post- clinic filter doses for nose breathers and a 
group of age-matched mouth breathers (n=4) is shown in figure 4.2 (the small 
numbers didn't allow demonstration of statistical significance). Despite the distinct 
discrepancy in drug delivery, technique evaluation scores (percent of correct skills 
demonstrated) were similar for both mouth breathers and nose breathers (95%, 86% 
respectively). The effect of nose breathing is further discussed in section 4.5.1. 
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Figure 4.2: Clinic pre- and post-training filter doses (±SD). Comparison of drug 
delivery between patients who performed mouth inhalation (n=4) and nose inhalation 
(n=4). 
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4.3 Drug Delivery in a Domiciliary Setting 
Daily domiciliary inspiratory filters were collected over a period of seven days to 
evaluate the difference in drug delivery in a more natural, non-clinical setting. 
There was no significant difference in drug delivery between the individual days 
(p=0.331) or the time of day (morning/evening) the medication was administered 
(p=0.326). There was also no significant effect depending on the type of spacer used 
and the day it was used (p=0.267), or the type of spacer used and time of day it was 
used (p=O .131). An overall significant difference was found between morning and 
evening doses, with evening administration exhibiting significantly higher drug 
delivery (p=O.OOl ). Within the FH group evening doses were also significantly 
higher (p=O.Ol5), however, no significant difference was found between morning 
and evening doses in the AC+ group (p=0.381) (Figure 4.3). Furthermore, a 
significant difference in drug delivery was found between the AC+ group and the FH 
group (p=0.032), with the children using the AC+ receiving a higher mean dose 
(Table 4.3). However, the AC+ group showed greater day-to-day variability, and had 
a consistently higher standard deviation for both morning and evening doses 
compared to the FH group (Figure 4.4). 
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Table 4.3: The average of the morning and evening doses (Jlg) for each of the seven 
days for the AC+ and FH spacer groups. The AC+ group had a significantly higher 
mean dose than the FH. 
AC+ FH 
Day 1 38.02 27.97 
Day2 38.08 27.33 
Day3 38.03 28.81 
Day4 40.02 27.79 
Day5 35.22 27.70 
Day 6 32.87 28.31 
Day7 33.39 28.03 
Mean (±SD) 36.52 (2.71) 27.99 (0.47) 
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Figure 4.4: Morning and evening doses (±SD) for the AC+ and FH spacer. Day-to-
day variability was greater in the AC+ group and the standard deviation for each day 
was consistently higher. 
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4.4 Drug Delivery in a Domiciliary and Clinical Setting 
Overall, there was no significant difference in drug delivery between the domiciliary 
setting and the clinic setting (p=0.75) (Figure 4.5). The mean drug dose between the 
two spacer groups in the clinic setting was not significantly different (AC+; 32.11 ~-tg 
±14.27, FH; 31.01 1-tg ±14.27) (p=0.735). On the other hand, when drug delivery was 
assessed in the domiciliary setting, the AC+ delivered significantly more drug 
(Figure 4.6). Identical results were obtained using the generalised estimating 
equation approach (weighted analysis). 
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Figure 4.5: Average drug dose (±SD) in the domiciliary and clinic setting. There 
was no significant difference in drug dose between the domiciliary setting and the 
clinic setting. 
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Figure 4.6: Average morning and evening doses (±SD) in the domiciliary setting and 
the post-training filters in the clinical setting. There was a significant difference in 
drug delivery between spacer groups in the domiciliary setting. However, there was 
no significant difference in the clinic setting. 
4.5 Flow-Volume Simulator Filter Dose Analysis 
This section examines in vitro the effects of age, height, weight and breathing 
parameters (tidal volume, inhalation volume, inhalation time, exhalation volume, 
exhalation time, peak inhalation flow, time to peak inhalation, peak exhalation flow 
and time to peak exhalation) on drug delivery. 
There were no significant differences in the breathing parameters between the AC+ 
spacer group and the FH spacer group (Table 4.4). Overall, correlations between 
drug delivery and the analysed parameters were weak (r2 = 0.005 - 0.272). When the 
two spacer groups were examined separately, significant correlations were found 
within the AC+ group but not the FH group. In the AC+ group drug delivery was 
significantly positively associated with peak inhalation flow (p=O.OOI), age 
(p=0.002), tidal volume (p=0.003), inhalation volume (p=0.003), exhalation volume 
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(p=0.004), height (p=0.005), weight (p=0.014) and peak exhalation flow (p=0.027) 
(Table 4.5). Peak inhalation flow and age were the most significantly associated with 
drug delivery; these two parameters are compared between the two spacer groups in 
figures 4.7 and 4.8. 
Table 4.4: The mean (standard deviation) of the different breathing parameters for 
the AC+ group and the FH group. There were no significant differences between the 
two groups. 
AC+ FH 
Breathing Parameters Mean (±SD) Mean (±SD) p-value 
Tidal volume (mls) 98.81 (65.76) 103.9 (36.36) p>0.05 
Inhalation Volume (mls) 47.88 (31.78) 44.71 (17.27) p>0.05 
Inhalation Time (sec) 0.83 (0.25) 0.93 (0.31) p>0.05 
Peak Inhalation Flow (mls/sec) 5646 (3329) 4537(1896) p>0.05 
Time to Peak Inhalation 6.41 (8.21) 4.47 (1 .34) p>0.05 
Exhalation Volume (mls) 50.73 (34.59) 58.73 (21.69) p>0.05 
Exhalation Time (sec) 1.23 (0.42) 1.02 (0.36) p>0.05 
Peak Exhalation Flow (mls/sec) 4001 (2727) 5052 (1771) p>0.05 
Exhalation Volume (mls) 50.73 (34.59) 58.96 (22.20) p>0.05 
Time to Peak Exhalation (mls/sec) 5.54 (1 .57) 5.18 (1.59) p>0.05 
Table 4.5: Parameters significantly associated with drug delivery in the AC+ group. 
Each parameter is shown in order of the strength of correlation (r2) and significance 
(p-value). 
Correlation 
Parameters (r2) p-value 
Peak Inhalation Flow 0.451 0.001 
Age 0.403 0.002 
Tidal volume 0.387 0.003 
Inhalation Volume 0.385 0.003 
Exhalation Volume 0.365 0.004 
Height 0.349 0.005 
Weight 0.278 0.014 
Peak Exhalation Flow 0.231 0.027 
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Figure 4.7: The effect of peak inhalation flow on drug dose. A: There was a 
significant correlation between PIF and drug dose in the AC+ group (r2= 0.451 , 
p=O.OOl). B: There was no significant correlation between PIF and drug dose in the 
FH group (r2= 0.008, p=0.691). 
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Figure 4.8: The correlation between age and drug dose. A: There was a significant 
correlation between age and drug dose in the AC+ group (r2= 0.403, p=0.002). B: 
There was no significant correlation between age and drug dose in the FH group (r2= 
0.005, p=0.745). 
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4.5.1 Nasal Inhalation 
Children who inhaled through their nose were further examined by analysis of 
individual breathing traces. The difference in breathing trace patterns between a 
typical mouth breather and a nose breather is shown in figure 4.9. As expected, the 
drug dose delivered to patients who perform nasal inhalations was extremely low. 
The difference in mean drug delivery between the nose breathers and a group of age-
matched mouth breathers (n=4) is shown in figure 4.10. The small numbers didn't 
allow demonstration of statistical.significance. This is only preliminary data; further 
analysis with a larger cohort is needed in order to attain a better understanding of this 
sub-group of patients. 
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Figure 4.9: Representative breathing traces. Negative flow represents inhalation and 
positive flow represents exhalation. A: Breathing trace of a mouth breather. B: 
Breathing trace of a nose breather; no inhalation is shown on breathing trace, thus the 
patient is inhaling through their nos~ and exhaling through their mouth. 
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Figure 4.10: A difference of 19.89 ~-tg (±SD) in drug delivery in vitro between 
mouth breathers (n=4) and nose breathers (n=4; mean age 51 months). 
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CHAPTERS 
DISCUSSION 
Ineffective drug delivery is a common problem in the paediatric age group, resulting 
in increased symptoms and a decreased quality of life for both children and parents 
[5-7]. In order to improve future asthma care, it is important to isolate the sources of 
variability in drug delivery and implement new tactics in an effort to improve drug 
delivery. The aim of this study was to examine factors that affect delivery of inhaled 
aerosol medications and investigate whether certain strategies improve drug delivery 
in pre-school age children. 
5.1 Clinic-Based Technique Training 
The pMDI-spacer combination is often used incorrectly by children and parents, 
causing sub-optimal drug delivery to the airways, and thus increasing the risk of 
adverse systemic side-effects and dangerous asthma exacerbations [5, 6, 129, 130]. 
The effect of clinic-based technique training on drug delivery was investigated in this 
section of the project. The population for the present study was recruited from an 
existing study with a larger cohort, where the children attended regular clinic 
sesswns for 12 months and received device technique training. The number of 
training sessions received from the larger study was dependent on the number of 
clinic visits attended, thus the children in the present sub-study had all obtained 
various amounts of training prior to their clinic session. 
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In the clinic session two drug delivery measurements were conducted with each 
child; a pre- and a post-training filter. The pre-filter sample was taken before the 
parent was trained on pMDI-spacer administration technique and the child on 
inhalation technique at that visit. Once the training session had occurred and errors 
were corrected a post-training filter sample was taken. 
In order to achieve the full benefits of therapy, effective inhaler technique is essential 
[15, 26, 124]. Former studies have not previously assessed the effects of clinic-based 
technique training by integrating a qualitative analysis (check-list score) with a 
measure of drug delivery. The present study evaluated the parent's pMDI technique 
and the child's inhalation technique, before and after training, according to a 
criterion check-list of essential procedures, whilst collecting measurements of drug 
delivery. The effect of immediate training was measured by comparison of the pre-
and post-training filters. Overall, there was no significant difference in drug delivery, 
or technique scores, between pre-training and post-training. Therefore, these results 
show that clinic-based training had no immediate positive effect on technique or drug 
delivery. From the qualitative analysis, the most common errors performed were 
parents not shaking the pMDI canister before every actuation and children taking 
their mouth away from the spacer after actuation; these findings are in accordance 
with other studies [103, 129, 132]. The greatest improvement in technique was 
parents shaking the pMDI canister before every actuation, and as this technique was 
dependent on the parent it was more easily corrected, as opposed to keeping a tight 
seal on the mouth piece of the spacer, which was dependent on the child. 
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Our laboratory has found that shaking the pMDI before every actuation is essential 
with corticosteroid suspension delivery (i.e. fluticasone ), as the drug particles 
separate rapidly from the propellant, resulting in minimal release of the effective 
compound (unpublished data). However, previous studies have shown that the drug 
particles do not separate as rapidly with salbutamol. This was originally shown using 
CFC salbutamol [144], and has been confirmed in our laboratory using HFA 
salbutamol (unpublished data). Therefore, once the pMDI canister has been 
rigorously shaken prior to the initial actuation, shaking between subsequent 
actuations is not essential. As salbutamol was used as a marker of drug delivery in 
this study, shaking may not have , caused a significant difference in drug dose, 
however, there may have been a great difference with inhaled corticosteroids. 
Fluticasone was deliberately not used in the present study due to the masking effect 
(i.e. not shaking the pMDI within seconds of actuation may result in huge changes in 
drug delivery), as a range of device technique issues were being examined, not just 
one. However, since the greatest improvement in technique was shaking of the pMDI 
canister, it would be worth assessing if this specific change in technique results in a 
significant improvement in delivery of corticosteroid suspension formulations. 
The effect of repeated training was also assessed by comparison of post-training 
filter doses (i.e. drug dose after training) with the total number of training sessions 
attended. At the end of the clinic visit all children had acquired two, three or four 
training sessions in total; this includes any previous training received from the larger 
study. The results obtained show that repeated pMDI-spacer technique training in 
pre-school children and their parents had no significant effect on drug delivery. 
Previous studies have found that regular training improves device technique skills in 
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both children and parents [17-21]. Based on a standardised check-list of essential 
technique steps, Kamps et al. [19] found that 93% of children (mean age 5 years) 
who had received at least two training sessions could perform all vital steps 
correctly, compared to 58% who had not received repeated training. Foland and 
colleagues [20] also assessed the effects of training in older patients (mean age 9.2 
years) and found that after repeated training children were able to perform at least 
seven out of eight essential steps correctly without prompting. However, these 
studies have some limitations, namely, the form of assessment was only qualitative; 
thus the patients technique, before and after training, was assessed by the 
investigator's perception of competence according to a criterion check-list of 
essential device administration procedures and skills. Additionally, these studies 
have not shown whether perceived improvement in technique correlates with 
improvement in drug delivery and clinical efficacy, which are the most relevant 
outcomes. Wilson et al. [145] incorporated an observational analysis (check-list 
score) with patient reports of asthma symptoms, and found that technique scores 
increased over a one year follow-up and self-reported asthma symptoms decreased. 
Nevertheless, it is well established that objective assessment is the most accurate, as 
it does not rely on patient reports and observation [13]. 
The present study integrated both qualitative and quantitative methods of assessment. 
Although it was anticipated that there would be a direct correlation between drug 
delivery and technique evaluation the results from the present study show that 
technique scores improved after three training sessions from baseline, but drug 
delivery did not. These results, along with other findings, suggest that while an 
observational analysis of technique may be adequate to correct gross errors which 
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may sufficiently impact on the efficiency of inhaler technique, more objective 
methods are needed to identify less obvious errors [146]. Pedersen et al. [129] 
showed that children who had previously been assessed with objective methods, such 
as lung function measurements, exhibited better technique, as errors were more 
readily noticed and corrected, compared to children who did not receive this form of 
training. This issue is of immense importance and has also been highlighted in the 
present study. By assessing drug delivery, it was possible to identify children who 
perform nasal inhalation. These children would not have been recognised by a 
standard observational analysis alone, and consequently the error in technique could 
not have been corrected. Patients who breathe through their nose inhale very little, if 
any drug into their body; hence an error that has a huge impact on drug delivery 
would have been unrecognised if an objective measure was not incorporated in the 
present study. 
This study assessed drug delivery, which is an intermediate measure between an 
observational analysis and clinical efficacy. Lung function measurements provide a 
more coherent evaluation of technique performance and clinical efficacy by showing 
whether the drug is actually inhaled into the lungs, which is the primary aim of 
training. Future studies should include objective measures based on clinical efficacy, 
such as lung function tests, to conclusively determine the effects of inhaler technique 
training and. ensure all essential skills are performed optimally. 
Qu~litative analyses of the clinic-based video-recordings were conducted to closely 
observe the manner in which the children interacted with the spacer devices. 
Children using the AC+ spacer appeared to be more focused on their inhalation 
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technique and the administration procedure, compared to the children using the FH 
spacer. Children with the FH spacer seemed to treat the spacer more like a toy, and 
thus were more likely to misbehave and less likely to concentrate on their breathing. 
Although these results are preliminary, it is plausible to suggest that perhaps children 
associate the FH spacer with 'play time', and as a result may be more inclined to play 
about during the administration procedure. However, the AC+ spacer may be seen as 
more of a 'medical device', which could possibly encourage children to adopt a more 
serious attitude during the administration procedure. The behaviour seen with the FH 
spacer is directly opposite to what was intended with the use of the incentive device. 
5.2 Drug Delivery in the Domiciliary Setting 
It is not only essential to assess drug delivery in a clinical setting, but also outside the 
clinic, in a more natural setting. The domiciliary setting provides a more realistic 
representation of drug delivery, as the 'white coat' effect disappears and the child is 
in a more comfortable environment. This section of the study assessed drug delivery, 
with use of the AC+ and FH spacer devices, in daily life over a period of one week. 
In order to keep the home environment as natural as possible a study supervisor was 
not present during the domiciliary study. 
The results obtained showed there was no difference in drug dose between individual 
days, thus the children did not perform better or worse on certain days. However, the 
AC+ spacer group exhibited significantly higher drug delivery consistently over the 
seven days compared to the FH spacer group. In addition, there were no differences 
between evening and morning doses in the AC+ group; however the FH group had 
significantly higher evening doses compared to morning doses. These findings 
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suggest that technique compliance and co-operation was greater with the AC+ spacer 
compared to the FH spacer. Moreover, the consistency between morning and evening 
doses in the AC+ group suggests that compliance to good technique was constant 
with the AC+ spacer regardless of the time of day the spacer was used, but not with 
the FH spacer. These results are in contradiction to Watt et al. [1] who found that 
adherence and technique compliance increased in children and parents with the FH 
spacer, compared to a standard spacer device, in the home setting over a two-week 
period. However, this study assessed the long-term effects of the FH spacer (all 
children had been using the FH for a period of three to nine months), using an 
objective measure, namely on drug delivery. The earlier study was conducted over a 
shorter period of time (two-weeks) using more subjective measures (parental report 
via questionnaire). Therefore, even though improvement in adherence and technique 
was previously seen, the results found here show that when children use the FH 
spacer over a longer period of time there is no improvement in drug delivery. An 
explanation for the two opposing findings could be that children are initially excited 
by the incentive toys and the novel device, however with constant use over time, the 
novelty begins to fade and children become bored. In addition, even though a study 
supervisor was not present during the domiciliary study, based on the clinic video 
evaluations, it is plausible to suggest that children who were using the FH spacer 
were more likely 'play about' in the home, compared to children using the AC+ 
spacer. Hence, this preliminary data demonstrates that particularly with prolonged 
use, 'toy' incentive devices may actually decrease co-operation and drug delivery to 
children. 
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5.3 Flow-Volume Simulator Drug Dose 
Isolating factors that are important in drug delivery in young patients is an essential 
step to improving health outcomes. This component of the project examined the 
effects of age, height, weight and breathing parameters (tidal volume, inhalation 
volume, inhalation time, exhalation volume, exhalation time, peak inhalation flow, 
time to peak inhale, peak exhalation flow and time to peak exhale) on in vitro drug 
delivery. Breathing traces were recorded from all children during their clinic session 
and were subsequently simulated using a FVS. 
The AC+ spacer showed a significant positive association between drug delivery and 
age, height, weight, tidal volume, peak inhalation flow, inhalation volume, 
exhalation volume and peak exhalation flow. However, no significant associations 
were found between any of the parameters investigated with the FH spacer. 
Age, height and weight are all indicators of lungs size [147, 148]; thus the positive 
. association between drug delivery and the age, height and weight of a patient 
suggests that the AC+ spacer provides a form of dose correction for lung size. This 
means smaller children will inhale less drug compared to larger children when using 
the AC+ spacer. The advantage of dose correction is that children receive a dose 
relative to their lung/body size, and as a result fewer side-effects will be experienced. 
This is especially important with inhaled corticosteroid treatment as there are many 
potential adverse side-effects associated with over treatment [28, 95]. 
Drug delivery with the FH spacer was shown to be independent of the child's age. 
Furthermore, the non-significant positive association between drug delivery and the 
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breathing parameters indicates that dose delivery is also independent of the patients 
breathing parameters. Therefore, the FH spacer would be ideal to use in emergency 
situations where the child may not be able to perform optimal breathing, but would 
still receive an adequate dose of medication independent of their age. An example of 
this could be in situations of airway obstruction, where the child will not be capable 
of performing effective breathing, but will need a large dose of a beta2 agonist 
independent of their age. 
5.3.1 Nasal Inhalation 
It is difficult to identify patients who perform nasal inhalation by observation, more 
objective measures are needed. As was the case in this study, children who inhaled 
through their nose were identified by assessment of drug delivery and analysis of 
individual breathing traces. There were a total of four children (AC+: n=2, FH: n=2) 
who were recognized as nose breathers; mean age 51 months (range: 30-60 months). 
These children were excluded from the overall analyses and were studied as a 
separate group. 
Drug delivery was compared between the identified nose breathers and a group of 
age-matched mouth breathers, and as expected the dose inhaled by patients who 
breathed nasally was extremely low. The results show that on average mouth 
breathers can inhale up to 24 ~g of drug, compared to nose breathers who only 
inhaled 4 ~g. The magnitude of this difference clearly illustrates that with each 
administration patients who inhale through their nose can receive up to 20 1-tg less 
drug than patients who breathe through their mouth. The use of a nose clip can be 
incorporated with each administration in an attempt to encourage mouth breathing; 
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however many children resist this and compliance becomes a problem, especially in 
the home where children are even less likely to be co-operative. These findings are 
preliminary and certainly warrant further investigation into this sub-group of 
patients. 
5.4 Comparison of the Two Spacer Devices (AC+ and FH) 
No significant difference was found in drug delivery between the two spacers in the 
clinic setting. However, when tested in the home, the AC+ spacer was shown to 
provide a significantly higher drug dose compared to the FH spacer. Previous 
literature has shown that there is' considerable variation in drug delivery from 
different spacer devices in daily life [1 0, 16]. The domiciliary setting, as opposed to a 
clinical setting, provides a more accurate representation of drug delivery and device 
use in a daily life situation, as this is the primary setting where drug administration 
occurs. Before prescribing an inhaler device, it is important for clinicians to consider 
that a child's performance in the clinic setting is not always reflected in a daily life 
situation. By examining the effects of the FH spacer in a clinical and domiciliary 
setting, it was found that even though the FH would be ideal to use in emergency 
situations, it would not be ideal for every day use. The children seemed to treat the 
FH spacer as too much of a toy, which caused the 'play' issue, and in tum 
compromised drug delivery. Hence, with long-term use the incentive effective of the 
FH spacer appears to vanish. 
Drug delivery with the AC+ spacer was shown to be dependent on the patient's 
breathing parameters. As children are more likely to show variation in their breathing 
technique, variability in drug delivery would also be more common with the AC+ 
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spacer. This was evident in the domiciliary study where more variability was seen 
between doses with the AC+ spacer. However, despite this, the AC+ spacer still 
delivered a significantly higher dose compared to the FH spacer. This suggests that 
children exhibit better technique and were more co-operative with the AC+ 
compared to the FH spacer. Thus, this study has shown that even though the AC+ 
spacer may have some limitations, children perform better in the home with the AC+ 
spacer, compared to an incentive spacer such as the FH. 
Due to time restrictions, this study was only able to provide preliminary data on 
inhaler technique training and the use of an incentive spacer device compared to a 
standard device in pre-school children. These issues will be more comprehensively 
analysed in the larger longitudinal study. Furthermore, this study was a non-blinded 
study, thus both investigators and subjects were aware of which spacer type was 
being used, however as one of study objectives was to evaluate the way children 
interact with the two different spacer devices, blinding was unsuitable. 
5.5 Future Research 
Both the present study and the longitudinal study examined drug delivery in terms of 
the 'total body dose' of drug inhaled by the patients, not drug delivery to the lungs, 
specifically; therefore future research will involve radio-labelling lung deposition 
studies, in order to evaluate the deposition of drug particles in the respiratory tract. 
Furthermore, increasing the sample size and furthering the development of new 
patient inhaler training strategies, particularly aimed at nose breathers, is another 
possible area for future research. 
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Parent Information Sheet 
Womevis:) 
C.\-;\dYeVI'S 
Heallh Service 
Effect of a paediatric incentive spacer and reinforcement of 
inhalation technique training on drug delivery to preschool children 
in both clinical and domiciliary settings. 
Randomisation Number: Subject Initials: __ 
Date of Birth: ___ / _______ / ________ _ 
Introduction: 
In addition to your participation in the Funhaler study we would like to invite your child to 
take part in a filter study that will assess the amount of medication he/she is inhaling. One 
component of the study will be conducted in the clinic and the other component will take 
place in your home. We will then compare the amount of medication delivered in a clinic 
versus a home setting. The reason for thjs study is to investigate whether the dose of asthma 
medication received by children is more variable when used daily in the home setting than 
when used in the hospital clinic setting. This study will involve a sub-group of 40 children 
from the Funhaler study. 
Overview: 
This information sheet provides a written overview of the study as well as an explanation of 
the procedures involved and will also be verbally discussed with you to ensure your 
complete understanding. Once you feel confident that you understand the study, and if you 
agree to allow your child to take part, you will be asked to sign a consent form. 
Before you learn more about this study, it is important to know that: 
Your child's participation is entirely voluntary. 
You can continue to participate in the Fun haler Study without taking 
part in this filter study. 
You can withdraw your child from the study (through verbal 
notification) at any time without compromising his/her routine medical 
care in any way. 
Background: 
Variability in drug delivery due to incorrect inhaler device technique and resistance to 
treatment is a common problem in paediatric asthma. The effect of clinic-based technique 
training in young children and their parents has not been extensively researched previously. 
Assessment of drug delivery in a clinical setting and a home setting will verify if clinical 
training improves technique and if this improvement correlated with non-variable drug 
delivery in the home. The Funhaler™ was developed in an attempt to alleviate children's fear 
of using standard asthma delivery devices. The devices currently available are difficult to use 
with small children and infants and therefore inefficient. The purpose of the Funhaler™ is to 
help overcome these difficulties by motivating the child to inhale willingly and effectively 
by the use of breath-driven toys attached to the device, such as whistles and spinning disks. 
This study will.build on previous research done at Princess Margaret Hospital. 
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Procedures: 
In the clinic visit you and your child will be asked to demonstrate your drug delivery 
technique pre and post training. During the procedure a filter will be placed between the 
spacer and your child's mouth so he/she will not receive any drug. The procedure will be 
videoed taped for qualitative analysis later. The video recordings will be stored electronically 
on a secure network folder which is password protected and will only be available to 
the investigator and supervisors. As part of the pre training analysis your 
administration technique and your child's breathing technique will be assessed and 
any errors will be corrected. A 1 minute training video will also be shown. To assess any 
improvement a post training analysis will then take place. 
Following this visit, 14 filters will be dispensed for the home filter study. For a week, you 
will be asked to give your child their normal prescribed medication first and then repeat the 
procedure with a filter. The filter will be inserted in between the spacer and your child's 
mouth. You will continue to give your child their normal asthma medication, and he/she will 
not inhale any additional drug when using the filters. You will be shown how to store the 
filters until we can arrange to collect them. 
Benefits associated with this study: 
By taking part in this study, your child will additionally support the development of a 
new form of asthma medication delivery from which he/she and other patients might 
benefit in the future. 
Risks associated with this Study: 
There are no risks involved. Your child's normal medication will not be interfered with in 
anyw~y. 
Confidentiality: 
Your child's research records will be confidential to the extent permitted by law. Your child 
will be identified by a code, and any personal information from his/her records will not be 
released. The information will always be treated confidentially and securely stored and you 
or your child will not be personally identified in any publications about this study. However, 
representatives of the ethics committee and from the regulatory bodies may check that the 
information collected 
during the study is accurate. 
Queries 
If you have any questions or require any further information about this study or your child's 
rights, please contact Jasminka Murdzoska on 9340 8452. If you have any complaints 
regarding the conduct of the study, please contact the Executive Director of Medical 
Services at Princess Margaret Hospital on 9340 8222. 
Thank you for taking the time to find out more about this study. 
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~FORM OF CONSENT 
Subject Initials: ___________ _ Randomisation Number: 
I, ......................................................................................... have had the study clearly explained 
tome 
(Given Names) (Surname) 
and I have read and understood the information sheet explaining the study entitled: 
Effect of a paediatric incentive spacer and reinforcement of inhalation technique training on 
drug delivery to preschool children in both clinical and domiciliary settings. 
Any questions I have asked have been answered to my satisfaction. 
I agree to allow the participation in this study of 
Daughter I 
Son 
(Full name of participant) (please circle) 
I understand I may decline to enter or withdraw my child from the study at any stage and 
without interfering with routine medical care. I have been made aware of my right to access 
and request correction of my child's personal data. I acknowledge that I have received a copy 
of this form for future reference. 
I agree that research data gathered from the results of this study may be published, provided 
that my child is not identified. I also give permission for the study investigators, independent 
auditors and other regulatory authorities if required to have access to my child's medical 
records, in the knowledge that all information will be treated as strictly confidential. 
Signature: .............................................................................. . 
Dated: ............. day of .................................................. 20 ........ .. 
I, .................................................................................................................. . 
(Investigator's full name and signature) 
have explained the nature, demands and foreseeable risks and benefits of the study to the 
person named above who stated he/she understood the same and have witnessed the 
completion of the consent form. 
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TECHNIQUE EVALUATION CHECK-LIST 
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TECHNIQUE EVALUATION 
PRE-TRAINING EVALUATION Time: 
----
Action Score 
Shaking pMDI before each actuation 
(O=no, 1 =sometimes, 2=always) 
Appropriate insertion of pMDI into spacer 
(O=no, 1 =yes) 
Placement of spacer in child's mouth 
(O=no, 1 =yes) 
Single dose actuation 
(O=no, 1 =yes) 
Five tidal breaths through spacer 
(O=child refuses, 1 =uneven/fast breathing, 2=s/ow even 
breathing) 
Actuation of appropriate number of doses 
(O=no, 1 =yes) 
Detachment of spacer from mouth after actuation 
(O=often, 1 =sometimes, 2=never) 
Extent of struggling 
(O=vigorous, 1=slight, 2=none) 
TOTAL SCORE 
COMMENTS: _______________ _ 
Signature/Date: ____________________ _ 
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POST-TRAINING EVALUATION 
Was the training video shown? 
If yes, which video? 
Aerochamber 
Action 
Shaking pMDI before each actuation 
(O=no, 1 =sometimes, 2=always) 
Appropriate insertion of pMDI into spacer 
(O=no, 1 =yes) 
Placement of spacer in child's mouth 
(O=no, 1 =yes) 
Single dose actuation 
(O=no, 1 =yes) 
Five tidal breaths through spacer 
Time: ____ _ 
01 Funhaler 
(O=child refuses, 1 =uneven/fast breathing, 2=slow even 
breathing) 
Actuation of appropriate number of doses 
(O=no, 1 =yes) 
Detachment of spacer from mouth after actuation 
(O=often, 1 =sometimes, 2=never) 
Extent of struggling 
(O=vigorous, 1 =slight, 2=none) 
TOTAL SCORE 
DoNo 
Score 
COMMENTS: ________________ _ 
Signature/Date: ____________________ _ 
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